Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121506 | 0.85 | TSHR (0.44) | ESR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL26586908 | 0.84 | KDM4E (0.38) | ESR1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1020226 | 0.82 | ESR1 (0.46) | ESR1KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL1021607 | 0.81 | HPGD (0.40) | KDM4EALDH1A1MAPTNPSR1CYP2C9 | |
| SCHEMBL6480994 | 0.81 | KDM4E (0.39) | ESR1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4473487 | 0.81 | KDM4E (0.40) | ESR1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3917609 | 0.81 | KDM4E (0.39) | ESR1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6705679 | 0.81 | ESR1 (0.54) | ESR1THRATHRBKDM4EALDH1A1 | |
| SCHEMBL30630148 | 0.81 | ESR1 (0.54) | ESR1THRATHRBKDM4EALDH1A1 | |
| SCHEMBL12428 | 0.81 | SMN1; SMN2 (0.54) | ESR1THRBKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2015-02-12 | — | — | US | disclosed |
| WO-2013138600-A1 | RADIOPROTECTOR COMPOUNDS | ROSEN ELIOT M (US) | 2013-09-19 | — | — | WO | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| EP-2323982-B1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | UNIV GEORGETOWN (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110152339-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | GEORGETOWN UNIVERSITY | 2011-06-23 | — | — | US | disclosed |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| WO-2010087430-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7238671-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238670-B2 | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152339-A1 | FLUORESCENT REGULATORS OF RASSF1A EXPRESSION AND HUMAN CANCER CELL PROLIFERATION | RASSF5, RASSF2, MKI67 | ESR1 2137/4885THRA 4005/4885THRB 4226/4885 |
| US-20070287670-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | ESR1 3362/4885THRA 462/4885THRB 429/4885 |
| US-20100210552-A1 | HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | GLP1R, IAPP, GIPR | ESR1 3362/4885THRA 462/4885THRB 429/4885 |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | ESR1 3682/4885THRA 2481/4885THRB 4261/4885 |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | DDB1, CASP3, BAD | ESR1 2781/4885THRA 3145/4885THRB 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.